Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives

被引：30

作者：

Patel, Jai N. ^{[1
]}

机构：

[1] Carolinas HealthCare Syst, Levine Canc Inst, Dept Canc Pharmacol, 1021 Morehead Med Dr,Rm 4336, Charlotte, NC 28204 USA

来源：

PHARMACOGENOMICS & PERSONALIZED MEDICINE | 2016年 / 9卷

关键词：

oncology; personalized; pharmacogenetics; germline; somatic; DNA; biomarker; CELL LUNG-CANCER; ELECTRONIC HEALTH RECORDS; MICROSATELLITE INSTABILITY; THIOPURINE METHYLTRANSFERASE; CLINICAL IMPLEMENTATION; GENETIC-POLYMORPHISM; 1ST-LINE TREATMENT; COLORECTAL-CANCER; RESISTANCE; GENOTYPE;

D O I：

10.2147/PGPM.S62918

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer pharmacogenomics is an evolving landscape and has the potential to significantly impact cancer care and precision medicine. Harnessing and understanding the genetic code of both the patient (germline) and the tumor (somatic) provides the opportunity for personalized dose and therapy selection for cancer patients. While germline DNA is useful in understanding the pharmacokinetic and pharmacodynamic disposition of a drug, somatic DNA is particularly useful in identifying drug targets and predicting drug response. Molecular profiling of somatic DNA has resulted in the current breadth of targeted therapies available, expanding the armamentarium to battle cancer. This review provides an update on cancer pharmacogenomics and genomics-based medicine, challenges in applying pharmacogenomics to the clinical setting, and patient perspectives on the use of pharmacogenomics to personalize cancer therapy.

引用

页码：65 / 77

页数：13

共 87 条

[61] Building a Rapid Learning Health Care System for Oncology: The Regulatory Framework of CancerLinQ [J].

Schilsky, Richard L. ;

Michels, Dina L. ;

Kearbey, Amy H. ;

Yu, Peter Paul ;

Hudis, Clifford A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (22) :2373-2379

[62] Oncogenic transformation and experimental models of human cancer [J].

Schinzel, Anna C. ;

Hahn, William C. .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :71-84

[63] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations [J].

Sequist, Lecia V. ;

Yang, James Chih-Hsin ;

Yamamoto, Nobuyuki ;

O'Byrne, Kenneth ;

Hirsh, Vera ;

Mok, Tony ;

Geater, Sarayut Lucien ;

Orlov, Sergey ;

Tsai, Chun-Ming ;

Boyer, Michael ;

Su, Wu-Chou ;

Bennouna, Jaafar ;

Kato, Terufumi ;

Gorbunova, Vera ;

Lee, Ki Hyeong ;

Shah, Riyaz ;

Massey, Dan ;

Zazulina, Victoria ;

Shahidi, Mehdi ;

Schuler, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3327-+

[64] Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial [J].

Shaw, Alice T. ;

Gandhi, Leena ;

Gadgeel, Shirish ;

Riely, Gregory J. ;

Cetnar, Jeremy ;

West, Howard ;

Camidge, D. Ross ;

Socinski, Mark A. ;

Chiappori, Alberto ;

Mekhail, Tarek ;

Chao, Bo H. ;

Borghaei, Hossein ;

Gold, Kathryn A. ;

Zeaiter, Ali ;

Bordogna, Walter ;

Balas, Bogdana ;

Puig, Oscar ;

Henschel, Volkmar ;

Ou, Sai-Hong Ignatius .

LANCET ONCOLOGY, 2016, 17 (02) :234-242

[65] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer [J].

Shaw, Alice T. ;

Kim, Dong-Wan ;

Nakagawa, Kazuhiko ;

Seto, Takashi ;

Crino, Lucio ;

Ahn, Myung-Ju ;

De Pas, Tommaso ;

Besse, Benjamin ;

Solomon, Benjamin J. ;

Blackhall, Fiona ;

Wu, Yi-Long ;

Thomas, Michael ;

O'Byrne, Kenneth J. ;

Moro-Sibilot, Denis ;

Camidge, D. Ross ;

Mok, Tony ;

Hirsh, Vera ;

Riely, Gregory J. ;

Iyer, Shrividya ;

Tassell, Vanessa ;

Polli, Anna ;

Wilner, Keith D. ;

Jaenne, Pasi A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25) :2385-2394

[66]

Shen L, 2014, NEW ENGL J MED, V370, P2537, DOI [10.1056/NEJMoa1311107, 10.1056/NEJMc1404894]

[67] Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer [J].

Soda, Manabu ;

Choi, Young Lim ;

Enomoto, Munehiro ;

Takada, Shuji ;

Yamashita, Yoshihiro ;

Ishikawa, Shunpei ;

Fujiwara, Shin-ichiro ;

Watanabe, Hideki ;

Kurashina, Kentaro ;

Hatanaka, Hisashi ;

Bando, Masashi ;

Ohno, Shoji ;

Ishikawa, Yuichi ;

Aburatani, Hiroyuki ;

Niki, Toshiro ;

Sohara, Yasunori ;

Sugiyama, Yukihiko ;

Mano, Hiroyuki .

NATURE, 2007, 448 (7153) :561-U3

[68] Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey [J].

Stanek, E. J. ;

Sanders, C. L. ;

Taber, K. A. Johansen ;

Khalid, M. ;

Patel, A. ;

Verbrugge, R. R. ;

Agatep, B. C. ;

Aubert, R. E. ;

Epstein, R. S. ;

Frueh, F. W. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (03) :450-458

[69] Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia [J].

Stanulla, M ;

Schaeffeler, E ;

Flohr, T ;

Cario, G ;

Schrauder, A ;

Zimmermann, M ;

Welte, K ;

Ludwig, WD ;

Bartram, CR ;

Zanger, UM ;

Eichelbaum, M ;

Schrappe, M ;

Schwab, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (12) :1485-1489

[70] Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia [J].

Stocco, G. ;

Cheok, M. H. ;

Crews, K. R. ;

Dervieux, T. ;

French, D. ;

Pei, D. ;

Yang, W. ;

Cheng, C. ;

Pui, C-H ;

Relling, M. V. ;

Evans, W. E. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) :164-172

← 1 2 3 4 5 6 7 8 9 →